Psyence Biomedical ( (PBM) ) has issued an announcement.
Psyence BioMed has announced a strategic investment in PsyLabs, establishing operations in Africa to enhance its ibogaine production capabilities. This move positions the company uniquely within the psychedelics sector, allowing it to control the quality of ibogaine from its natural source to the finished product. The investment strengthens Psyence BioMed’s supply ...
Psyence Biomedical (PBM) established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the …
With PsyLabs, Psyence BioMed secures GMP ibogaine from sustainable iboga bark, processing 50 kg into ibogaine HCL and Total Alkaloid Extracts for …
Psyence Biomedical Ltd. announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs. This collaboration with PsyLabs is an important step in securing a long-term supply ...
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels ...